Aurobindo Pharma: Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12…
Aurobindo Pharma (AUROPHARMA) filed a disclosure titled "Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg". The company is valued at about ₹96,479 crore.
What happened
Aurobindo Pharma (AUROPHARMA) filed a disclosure with the exchanges on 3 October 2026 at 05:03 PM titled "Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg".
Company snapshot
Aurobindo Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹96,479 crore.
The stock last traded at ₹1,676.8, against a 52-week range of ₹1,066.8–₹1,740 (3.6% below the high).
Before this filing the shares had moved +1.7% over the month and +5.2% over three months. Average daily turnover over the last 20 sessions was about ₹129 crore.
Promoters held 51.88% at the end of Q1 FY27, up 0.06% points from the previous quarter; 13.75% of promoter shares were pledged. Foreign institutions owned 16.38% and domestic institutions 25.10%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 7,868 | 824.8 | 14.2 |
| Q2 FY26 | 8,286 | 848.5 | 14.61 |
| Q3 FY26 | 8,646 | 910.3 | 15.67 |
| Q4 FY26 | 8,853 | 921.3 | 15.86 |
| Q1 FY27 | 9,150 | 1,032.6 | 17.86 |
What history shows
BCEIE's records show 3 previous approval filings from the company since May 2026.
After those filings, the stock fell 2.2% on average the next trading day and was up 0.8% on average after five days (3 filings with price data).
Across 102 similar disclosures by other Healthcare companies, shares moved +0.4% on average the next day and +1.2% over five days; 52% of them rose the next day.
Market-wide, 1,489 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 15 Sept 2026 | A press release dated September 15, 2026, titled "Aurobindo Pharma… | −2.2% | +1.2% |
| 21 Jul 2026 | ANVISA Approval For Curateq Biologics'' Biosimilars Manufacturing… | −3.6% | +0.7% |
| 4 Jun 2026 | Approval | −0.8% | +0.6% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong
- Aurobindo Pharma Faces ₹4.60 Cr GST Demand
- Aurobindo Pharma Completes Acquisition Of A1 Biochem Labs LLC For $15.247 Million
- Aurobindo Pharma launches Adquey in US; Nuvama sees $300 million peak sales - CNBC TV18
- AUROPHARMA Outlook for the Week (September 28, 2026 – October 02, 2026)
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.